ReviewBone research2026
Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation.
Review in Bone research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone aging is not merely a process of bone mass loss but rather a multi-level, networked degenerative phenomenon spanning molecular, cellular, tissue, and system levels. With the accelerating pace of global population aging, bone degenerative diseases have emerged as a major public health challenge. Consequently, there is an urgent need to elucidate the underlying mechanisms from an integrated perspective and to develop innovative intervention strategies. This review systematically synthesizes the comprehensive landscape of bone aging. At the macroscopic level, bone aging is characterized by declines in bone mass, microstructure, and biomechanical properties, ultimately leading to increased fragility. At the microscopic level, its pathogenesis involves dysfunction across multiple layers. Molecular mechanisms include genetic and epigenetic alterations, oxidative stress, the senescence-associated secretory phenotype, and dysregulation of key signaling pathways. Cellular level changes involve telomere attrition, mitochondrial and endoplasmic reticulum dysfunction, impaired proteostasis, altered nutrient sensing, and cellular senescence. At the microenvironmental and systemic levels, contributing factors include chronic inflammation, hormonal changes, and extracellular matrix remodeling. Correspondingly, intervention strategies include non-pharmacological approaches, such as dietary optimization, physical activity, and avoidance of alcohol and tobacco, as well as pharmacological therapies, including antiresorptive agents, anabolic bone-forming drugs, and senolytics. Emerging therapeutic avenues include regenerative medicine, gene therapy, and tissue engineering. Future research should focus on constructing a multi-omics-integrated bone aging atlas, developing bone organoids and computational models, establishing multimodal risk assessment systems, advancing precision therapies that target aging-related pathways, and promoting prevention-centered public health strategies. This review aims to provide a systematic framework for understanding the complex pathophysiology of bone aging and to provide key insights and directions for future interdisciplinary collaborations, translational research, and clinical interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.